If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
ZypAdhera Summary of Product Characteristics (SmPC)
During treatment dose may be adjusted on the basis of individual clinical status. After clinical reassessment dose may be adjusted within the range 150 mg to 300 mg every 2 weeks or 300 to 405 mg every 4 weeks.
should be monitored carefully for signs of relapse during the first
one to two months of treatment.1
antipsychotic treatment, improvement in the patient's clinical
condition may take several days to some weeks. Patients should be
closely monitored during this period.1
treatment, dose may subsequently be adjusted on the basis of
individual clinical status. After clinical reassessment, dose may be
adjusted within the range 150 mg to 300 mg every 2 weeks or 300 to
405 mg every 4 weeks (Table 1).1
1. Recommended dose scheme between oral olanzapine and olanzapine
oral olanzapine dose
starting dose of olanzapine pamoate
dose after 2 month of olanzapine pamoate treatment
or 405 mg/4 weeks
or 300 mg/4 weeks
or 405 mg/4 weeks
specific patient populations may require lower starting doses and
cautious dose escalation.2
For full information please refer to the summary of product
oral olanzapine supplementation is clinically indicated, then the
combined total dose of olanzapine from both formulations should not
exceed the corresponding maximum oral olanzapine dose of 20 mg/day.1
ZypAdhera [summary of product characteristics] Eli Lilly Netherland
B.V., The Netherlands.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review:May 01, 2019
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org